Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility.
about
Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase.Progress in the development of new therapies for herpesvirus infectionsThe biology of cytomegalovirus drug resistanceLate emergence of A594V and L595W mutations related to ganciclovir resistance in a patient with HCMV retinitis and long-term HIV progressionHighlights in antiviral drug research: antivirals at the horizon.Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients.The development of new therapies for human herpesvirus 6.Cytomegalovirus mutants resistant to ganciclovir and cidofovir differ in susceptibilities to synguanol and its 6-ether and 6-thioether derivatives.Metabolism of cyclopropavir and ganciclovir in human cytomegalovirus-infected cells.Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions.Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance.Human herpesvirus vaccines and future directions.Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure.The D-form of a novel heparan binding peptide decreases cytomegalovirus infection in vivo and in vitro.Potency and Stereoselectivity of Cyclopropavir Triphosphate Action on Human Cytomegalovirus DNA Polymerase.Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance.Resistance of human cytomegalovirus to cyclopropavir maps to a base pair deletion in the open reading frame of UL97.Antiviral treatment of cytomegalovirus infection: an update.Antiviral Drugs for EBV.
P2860
Q35270303-5F1D0D12-3A9A-412E-A07A-6621C94E02DAQ35590695-DDF25ABD-E641-4E87-A3A3-FEE0B57F6EF4Q35684511-DFEC4C2F-6DFF-4D55-B905-255B78F8D8E7Q36057209-35562866-B66F-4368-8F0D-DDCBC14440E0Q38007145-2E800CAA-C00E-4801-8900-A11377209579Q38067694-3159C858-FB54-4ACC-BE88-D3B47122D178Q38280949-7867C432-6B8E-4B3A-B1E4-24CFDFB4FB92Q38324789-7E83A4AB-CAA2-4959-B8EC-FF3C9CE2A9EFQ39025231-5201AEA9-AC55-4F92-9069-75AC808F291EQ39074863-CB728B8F-28AB-475C-BB8E-17C70E8B54ACQ39155340-BBF7D76C-951F-4822-B0B3-B372F3743375Q39476453-6C6F777F-82AD-42F2-BE3F-8EBDFEE08136Q40325104-EE0F251E-9F8A-4531-BF93-6F4804EC3C41Q40483485-D44CE91C-9D48-4542-A7E0-348891BD2358Q40771642-6FE95D09-BAE1-42DC-A273-B1C095131032Q41060769-01F8782D-7855-4340-8878-22227BB1E347Q42286758-85141968-499B-409C-AD9D-F96DD2F9629EQ43992958-42839FEA-5AE5-427B-A067-082F5E0807D6Q55461330-2E8889DD-863C-4DE5-9122-738B8614F3B0
P2860
Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility.
@ast
Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility.
@en
Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility.
@nl
type
label
Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility.
@ast
Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility.
@en
Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility.
@nl
prefLabel
Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility.
@ast
Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility.
@en
Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility.
@nl
P2860
P356
P1476
Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility.
@en
P2093
Sunwen Chou
Terry L Bowlin
P2860
P304
P356
10.1128/AAC.01259-10
P407
P577
2010-11-01T00:00:00Z